NCT06066255View on ClinicalTrials.gov

PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hematological Malignancy
Interventions
DRUG

Thymoglobulin Injectable Product

single intravenous injection of thymoglobulin

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Institut Paoli-Calmettes

OTHER